🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Business news, market intelligence, and global industry analysis.
The Latest

Dr. Reddy’s Labs launches Posaconazole Delayed-Release Tablets in US

bySrinath
April 20, 2022
Total
0
Shares
0
0
0

Dr. Reddy’s Laboratories said that it has launched Posaconazole Delayed-Release Tablets, 100 mg, a triazole antifungal drug, in the US market.

Posaconazole Delayed-Release Tablets is the therapeutic generic equivalent to NOXAFIL (posaconazole) Delayed-Release Tablets, 100 mg, which has approval from the US Food and Drug Administration.

Dr. Reddy's Labs launches Posaconazole Delayed-Release Tablets in US
Dr. Reddy’s Labs launches Posaconazole Delayed-Release Tablets in US. Photo courtesy of Karthikndr/Wikimedia Commons.

According to IQVIA, the NOXAFIL brand and generic had sales of nearly $140.8 million MAT in the US for the most recent 12 months ending in February 2022.

Dr. Reddy’s Posaconazole Delayed-Release Tablets have been launched in 100 mg strength in bottle count sizes of 60.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Annexon gets FDA fast track status for ANX005 in Guillain-Barré Syndrome

Annexon Biosciences has bagged the fast track designation for its C1q inhibitor ANX005 from the US Food and Drug Administration (FDA) for the treatment of Guillain-Barré Syndrome (GBS). Considered to be a rare, acute, antibody-mediated autoimmune disease, Guillain-Barré Syndrome affects the peripheral nervous system for which there are no approved therapies in the US till […]

The post Annexon gets FDA fast track status for ANX005 in Guillain-Barré Syndrome appeared first on PharmaNewsDaily.com.

bypharmanewsdaily